Amiel Balagtas
Vice President, Development Operations at Corcept Therapeutics- Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Gold Feature
Click to upgrade to our gold package
for the full feature experience.
Location
San Mateo, California, United States, US
Topline Score
Bio
Generated by
Topline AI
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
0
/5.0 / Based on 0 ratingsFilter reviews by:
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
No reviews to display
There are currently no reviews available.
You need to have a working account to view this content.
Click here to join now
Experience
-
Corcept Therapeutics
-
United States
-
Biotechnology Research
-
200 - 300 Employee
-
Vice President, Development Operations
-
Mar 2022 - Present
-
-
-
Gilead Sciences
-
United States
-
Biotechnology Research
-
700 & Above Employee
-
Executive Director, Development Systems
-
May 2021 - Mar 2022
-
-
Executive Director, Medical Communications & Operations
-
Sep 1998 - May 2021
-
-
-
University of California, San Francisco
-
United States
-
Higher Education
-
700 & Above Employee
-
Cardiology
-
1997 - 1998
-
-
-
Stanford School of Medicine
-
United States
-
Higher Education
-
1 - 100 Employee
-
Stanford/VA Alzheimer's Research Center
-
1995 - 1996
-
-
-
University of California, Los Angeles
-
Information Services
-
1 - 100 Employee
-
Cardiothoracic Surgery
-
1993 - 1996
-
-
-
John Wayne Cancer Institute
-
United States
-
Civic and Social Organizations
-
Clinical Research
-
1990 - 1993
-
-
Education
-
UCLA
Bachelor of Science - BS -
Golden Gate University, Edward S. Ageno School of Business
Masters in Business Administration
Community
You need to have a working account to view this content.
Click here to join now